| Kristine Beaver, | |
|
730 East 500 South, Blanding, UT 84511 | |
| (435) 773-3988 | |
| Not Available |
| Full Name | Kristine Beaver |
|---|---|
| Gender | Female |
| Speciality | Clinical Nurse Specialist - Adult Health |
| Location | 730 East 500 South, Blanding, Utah |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1710393830 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 364SA2200X | Clinical Nurse Specialist - Adult Health | 364787915 (Utah) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kristine Beaver, 730 East 500 South, Blanding, UT 84511 Ph: (435) 773-3988 | Kristine Beaver, 730 East 500 South, Blanding, UT 84511 Ph: (435) 773-3988 |
News Archive
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended broadening the existing marketing authorization for Darzalex® for use as frontline therapy.
When David Vega fell ill with the novel coronavirus in mid-March, fever, chills and nausea left the 27-year-old Indiana medical student curled up in bed for days.
A new stem cell-based approach to studying epilepsy has yielded a surprising discovery about what causes one form of the disease, and may help in the search for better medicines to treat all kinds of seizure disorders.
Researchers with UCLA's Jonsson Comprehensive Cancer Center have developed and used a high-throughput molecular screening approach that identifies and characterizes chemical compounds that can target the stem cells that are responsible for creating deadly brain tumors.
› Verified 3 days ago